This update was necessary because of evidence suggesting that a sufficient number of patients with pancreatic cancer carry alterations in high-penetrance breast and ovarian cancer susceptibility genes that warrant testing, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, among others.1 Identifying a mutation in 1 of these genes in a patient could have significant implications for clinical decision making. Read more . . .
The current national Comprehensive Cancer Network (NCCN) Guidelines for Genetic/Familial High-Risk Assessment, Version 1.2020, have been expanded to provide information about pancreatic cancer in addition to recommendations regarding genetic testing in patients with breast and ovarian cancer.